MRD crossed from risk signal to treatment selector.
FDA's May 2026 adjuvant atezolizumab approval in ctDNA MRD-positive muscle-invasive bladder cancer made residual disease a concrete regulatory routing surface.
OncologyMRDNeoantigen vaccinesImmuno-oncology
Oncology
As of June 2026, oncology is moving from late-line tumor control toward earlier molecular routing. ctDNA molecular residual disease, adjuvant immunotherapy, personalized neoantigen vaccines, ADCs, bispecifics, and conditional immune platforms are changing what must be measured before a program is credible.
Domain research lens
This page tracks the research fronts that change buyer decisions: when residual disease becomes actionable, when recurrence prevention is testable, and when next-generation immuno-oncology platforms widen therapeutic index instead of relocating risk.
June 2026 field state
A field shifting from tumor treatment to recurrence-window strategy.
The strongest work now asks whether a biological state can route action before visible progression: ctDNA MRD, vaccine-solvency windows, tumor immune geometry, antigen heterogeneity, resistance anticipation, and biomarker-controlled therapeutic index.
Cancer biology, molecular residual disease, recurrence prevention, immuno-oncology, therapeutic resistance, early intervention, and evidence standards for cancer programs.
The domain thesis: oncology's next strategic edge is knowing which invisible disease state is real enough, actionable enough, and powered enough to justify intervention before recurrence.
Personalized vaccines can be tested in minimal-disease windows.
Durable neoantigen-vaccine immune responses and adjuvant trials make recurrence prevention a live program question, not only an immunology concept.
Surrogates can outrun benefit.
ctDNA clearance, immune response, radiographic response, and single-arm activity still need recurrence-free survival, overall survival, durability, and safety proof.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
ctDNA MRD became an FDA-linked adjuvant treatment selector.
FDA approved atezolizumab after cystectomy for adults with muscle-invasive bladder cancer who have ctDNA molecular residual disease by an FDA-authorized test.
Why it matters
MRD diligence must now separate prognostic risk from treatment-selection evidence, assay timing, serial testing, and survival-linked endpoints.
Decision implication
Moves MRD from monitor-only logic toward treatment-trigger logic.
Personalized vaccine data are moving into recurrence-window economics.
Recent individualized mRNA vaccine studies report durable T-cell immunity in adjuvant settings, while pancreatic and melanoma programs continue testing recurrence prevention.
Why it matters
Vaccine value depends on whether sequencing, manufacture, dosing, immune expansion, and MRD timing fit inside the recurrence window.
Decision implication
Changes vaccine diligence from antigen ranking to window solvency.
ADCs keep advancing, but safety and selection define the ceiling.
FDA approved datopotamab deruxtecan for unresectable or metastatic TNBC in adults not candidates for PD-1/PD-L1 inhibitor therapy.
Why it matters
Payload delivery is not enough without patient selection, toxicity management, antigen-loss logic, and combination discipline.
Decision implication
Shifts platform review toward therapeutic-index proof.
Adjuvant oncology is becoming a recurrence-risk selection problem.
FDA approved belzutifan plus pembrolizumab as adjuvant treatment for high-risk clear-cell renal cell carcinoma after nephrectomy or metastasectomy.
Why it matters
Earlier treatment only becomes interception when the selected risk state changes outcome enough to justify burden and toxicity.
Decision implication
Forces endpoint hierarchy across risk, recurrence, treatment burden, and durable benefit.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
MRD regulation
ctDNA-positive adjuvant treatment selection
FDA's atezolizumab decision and the Signatera companion diagnostic approval make residual disease a treatment-routing surface. The open question is which tumor types can move from prognostic monitoring to treatment-trigger evidence.
Neoantigen vaccinesPersonalized vaccines in minimal-disease windows
Nature-reported TNBC and pancreatic vaccine work keeps the field focused on whether sequencing, manufacture, dosing, and immune expansion can fit inside recurrence-prevention timelines.
Targeted payloadsADC expansion with safety-profile differentiation
TROP2, HER2, HER3, B7-H3, and other ADC programs now need organ-specific toxicity, payload sequencing, antigen-loss, and combination logic alongside response rate.
Immune geometryBispecifics, masked antibodies, and PD-1/VEGF constructs
The immuno-oncology frontier is less about adding stimulation and more about constraining where, when, and in which tumor state immune activation becomes tolerable.
RadiotheranosticsTargeted radiopharmaceutical therapy moves beyond prostate and NET playbooks
Radioligand therapy is becoming a broader precision-oncology modality, but trial design, dosimetry, imaging selection, supply chain, and marrow toxicity still decide translation.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
MRD actionability
Can the assay, timing, treatment choice, and endpoint prove actionability rather than risk alone?
Interception window
Can sequencing, manufacturing, dosing, and immune priming beat the recurrence clock?
Therapeutic index
Does a new ADC, engager, or bispecific widen the window or merely relocate toxicity?
Tumor heterogeneity
Which clone, antigen, immune state, or microenvironment feature breaks the thesis?
Endpoint discipline
Which endpoint decides continuation: immune response, ctDNA movement, DFS, RFS, OS, or safety?
Combination burden
Does complexity explain which patients, dose, sequence, and failure mode are being solved?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
MRD-Guided Neoantigen Vaccines
Links MRD timing, antigen selection, vaccine manufacture, immune response, and recurrence endpoints into a recurrence-prevention decision gate.
Why it belongs here
Which MRD-guided vaccine strategies have enough timing, manufacturing, immune-response, and endpoint logic to justify next-step validation?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Next-Generation Immuno-Oncology Platforms
Separates IO platform promise from therapeutic-index reality across potency, specificity, resistance, safety, and combination logic.
Why it belongs here
Which next-generation IO programs improve therapeutic index rather than simply adding potency, complexity, or combination burden?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
AI Biology Drug Discovery
Separates static generation wins from the harder validation problem: whether AI can predict dynamic biological response under prospective tests.
Why it belongs here
Which AI-biology programs deserve validation spend now, and what experiment would show whether the model changes a real discovery decision?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
AI Clinical Validation & Digital Biomarkers
Turns AI and digital biomarkers into validation-gate questions: prospective utility, generalization, drift, fairness, and endpoint acceptance.
Why it belongs here
Which AI or digital-biomarker claims are ready for prospective validation, and which are still retrospective performance stories?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Partial Epigenetic Reprogramming
Maps the rejuvenation-transformation margin so buyers can distinguish clock movement from functional, controlled, and safe benefit.
Why it belongs here
Which partial-reprogramming programs have enough control, reversibility, and safety-margin evidence to justify next validation?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
MRD actionability
Additional FDA-authorized MRD-linked treatment uses
More approvals would clarify when ctDNA should trigger therapy rather than surveillance.
Cancer vaccinesRandomized recurrence-free survival durability
Durable T-cell responses will matter only if they translate into recurrence, survival, or treatment-sparing benefit.
ADCsPayload safety separated from antigen loss and resistance
The field needs platform-level safety logic, not one-product response stories.
RadiopharmaTheranostic expansion with reproducible dosimetry
New RPT programs need imaging selection, absorbed-dose logic, isotope supply, and toxicity monitoring that scale beyond specialist centers.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
May 2026 / MRD regulation
The field now has a concrete example of ctDNA MRD routing adjuvant therapy.
Future oncology diligence should ask whether an assay is merely prognostic or has treatment-selection evidence tied to outcome.
2025-2026 / Neoantigen vaccines Personalized vaccine feasibility is no longer the whole question.The gating question is whether manufacture, immune priming, and monitoring fit the recurrence-prevention interval.
June 2026 / Oncology approvals Approvals keep moving earlier and becoming more biomarker-routed.Earlier-stage use raises the burden for patient selection, treatment duration, and toxicity justification.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.